Expression of HLA Class I, TAP 1, and TAP 2 in H-RS Cells
HD Case . | Subtype . | EBV Status . | HLA Class I . | TAP 1 . | TAP 2 . | |
---|---|---|---|---|---|---|
EBER in situ Hybridization . | LMP 1 Staining . | |||||
1 | MC | + | + | +++ | ++ | ++ |
2 | MC | + | + | +++ | ++ | ++ |
3 | MC | + | + | + | + | + |
4 | MC | + | + | +++ | +++ | +++ |
5 | MC | + | + | ++ | + | ++ |
6 | MC | + | + | ++ | ++ | ++ |
7 | NS | + | + | ++ | ++ | ++ |
8 | NS | + | + | ++ | ++ | ++ |
9 | NS | + | + | ++ | ++ | + |
10 | NS | + | + | ++ | ++ | + |
11 | NS | + | + | ++ | ++ | ++ |
12 | NS | + | + | ++ | ++ | ++ |
13 | NS | + | + | + | + | ++ |
14 | NS | + | + | ++ | ++ | + |
15 | NS | + | + | ++ | + | ++ |
16 | NS | + | + | + | +++ | ++ |
17 | NS | + | + | − | + | +/− |
18 | NS | + | + | − | ++ | +/− |
19 | NS | + | + | − | ++ | ++ |
20 | NS | + | + | − | ++ | ++ |
21 | LP | + | + | +/− | +++ | + |
22 | LP | + | + | − | ++ | ++ |
23 | IF | + | + | ++ | ++ | ++ |
24 | IF | + | + | ++ | ++ | ++ |
25 | MC | − | − | ++ | ++ | ++ |
26 | MC | − | − | +/− | +++ | +++ |
27 | NS | − | − | ++ | ++ | +++ |
28 | NS | − | − | − | +++ | ++ |
29 | NS | − | − | − | +++ | ++ |
30 | NS | − | − | − | ++ | ++ |
31 | NS | − | − | − | ++ | ++ |
32 | NS | − | − | − | ++ | ++ |
33 | NS | − | − | − | ++ | ++ |
34 | LP | − | − | +/− | ++ | ++ |
35 | LP | − | − | − | +++ | +++ |
36 | LP | − | − | − | +/− | ++ |
37 | ni | − | − | + | + | + |
38 | ni | − | − | + | ++ | ++ |
HD Case . | Subtype . | EBV Status . | HLA Class I . | TAP 1 . | TAP 2 . | |
---|---|---|---|---|---|---|
EBER in situ Hybridization . | LMP 1 Staining . | |||||
1 | MC | + | + | +++ | ++ | ++ |
2 | MC | + | + | +++ | ++ | ++ |
3 | MC | + | + | + | + | + |
4 | MC | + | + | +++ | +++ | +++ |
5 | MC | + | + | ++ | + | ++ |
6 | MC | + | + | ++ | ++ | ++ |
7 | NS | + | + | ++ | ++ | ++ |
8 | NS | + | + | ++ | ++ | ++ |
9 | NS | + | + | ++ | ++ | + |
10 | NS | + | + | ++ | ++ | + |
11 | NS | + | + | ++ | ++ | ++ |
12 | NS | + | + | ++ | ++ | ++ |
13 | NS | + | + | + | + | ++ |
14 | NS | + | + | ++ | ++ | + |
15 | NS | + | + | ++ | + | ++ |
16 | NS | + | + | + | +++ | ++ |
17 | NS | + | + | − | + | +/− |
18 | NS | + | + | − | ++ | +/− |
19 | NS | + | + | − | ++ | ++ |
20 | NS | + | + | − | ++ | ++ |
21 | LP | + | + | +/− | +++ | + |
22 | LP | + | + | − | ++ | ++ |
23 | IF | + | + | ++ | ++ | ++ |
24 | IF | + | + | ++ | ++ | ++ |
25 | MC | − | − | ++ | ++ | ++ |
26 | MC | − | − | +/− | +++ | +++ |
27 | NS | − | − | ++ | ++ | +++ |
28 | NS | − | − | − | +++ | ++ |
29 | NS | − | − | − | +++ | ++ |
30 | NS | − | − | − | ++ | ++ |
31 | NS | − | − | − | ++ | ++ |
32 | NS | − | − | − | ++ | ++ |
33 | NS | − | − | − | ++ | ++ |
34 | LP | − | − | +/− | ++ | ++ |
35 | LP | − | − | − | +++ | +++ |
36 | LP | − | − | − | +/− | ++ |
37 | ni | − | − | + | + | + |
38 | ni | − | − | + | ++ | ++ |
Abbreviations: MC, mixed cellularity; NS, nodular sclerosing; LP, lymphocyte predominant; IF, interfollicular HD; ni, not interpretable; −, no staining; +/−, only some cells positive; +, weak staining; ++, medium staining; +++, strong staining.